Navigation Links
Clinical Data Published in 'Science' Show Tumor Regressions in Relapsed Lymphoma Patients Treated with T Cell Engaging BiTE Antibody Blinatumomab
Date:8/14/2008

First T cell engaging antibody (BiTE) showing clinical benefit in cancer patients; Blinatumomab enables patients own T cells to recognize and attack

cancer cells

BETHESDA, Md., Aug. 14 /PRNewswire-FirstCall/ -- Micromet, Inc. (Nasdaq: MITI), a biopharmaceutical company developing novel, proprietary antibodies for the treatment of cancer, inflammation and autoimmune diseases, today announced publication of a Phase 1 clinical study(1) on its BiTE(R) antibody blinatumomab (MT103/MEDI-538) in this week's issue of Science. The article is available at http://www.sciencemag.org. Blinatumomab is being co-developed with MedImmune.

Blinatumomab is a novel antibody therapy that activates a patient's T cells to seek out and destroy cancer cells. The phase 1 study demonstrated tumor regression, and in some cases, complete remission, in non-Hodgkin's lymphoma patients who relapsed after previous treatments and were considered to have incurable disease. Most of the remissions are reported to continue, with the longest remission ongoing for more than one year. Results from this ongoing Phase 1 clinical trial with the CD19-specific BiTE antibody blinatumomab show that all seven patients treated to date at 0.06 mg/m2 per day achieved complete or partial responses. The safety profile observed in this study supports continued blinatumomab development.

"These results represent significant progress of a T cell engaging antibody for treatment of lymphoma patients as single agent therapy. We observed tumor regression in patients at serum levels of blinatumomab, which are approximately five orders of magnitude lower than serum levels needed by conventional m
'/>"/>

SOURCE Micromet, Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6

Related medicine technology :

1. Clinical Trials Bootcamp Announces Inaugural Meeting
2. Aon eSolutions Launches Clinical Trials Module
3. Aon: Complex Insurance Requirements, Risk Management Needs Challenge Firms Conducting Clinical Trials Beyond Own Borders
4. NewCardio Announces Positive Results From Third Clinical Validation Study
5. Isis Initiates Clinical Trial of CRP Drug
6. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
7. Medarex Announces Initiation of Phase 2 Clinical Development Program for the Treatment of Lupus
8. Journal of the American Dental Association Publishes Key Clinical Data for the Use of OraVerse(TM) a Local Anesthetic Reversal Agent
9. Cell Therapeutics Announces that the European Organization for Research and Treatment of Cancer Completes Enrollment in Phase II Clinical Trial of Brostallicin as First Line Therapy for Advanced or Metastatic Soft Tissue Sarcoma
10. M. D. Anderson to Initiate Clinical Validation Study on Rosetta Genomics MicroRNA-based Diagnostic Assay Identifying the Origin of Cancer Metastases
11. Innocoll Announces Dosing of Last Patient in US Phase 2 Clinical Trial to Investigate CollaRx(R) BUPIVACAINE SURGICAL IMPLANT for the Management of Post-Operative Pain
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/4/2009)MORRISTOWN, N.J., Dec. 4 Watson Pharmaceuticals, Inc. (NYSE: WPI ), a leading global specialty pharmaceutical company, today confirmed that its subsidiary, Watson Laboratories, Inc.-Florida, filed
(Date:12/4/2009)WILMINGTON, Del., Dec. 4 AstraZeneca (NYSE: AZN ) today announced that the US Food and Drug Administration (FDA) has approved once-daily SEROQUEL XR® (quetiapine fumarate) Extended Release Tab
(Date:12/3/2009)ALISO VIEJO, Calif. and STATE COLLEGE, Pa., Dec. 3 Ambry Genetics and SoftGenetics today announced the signing of an agreement to provide extended bioinformatics genomics services using SoftGenetics,
Breaking Medicine Technology:Watson Files FDA Application for Generic Rozerem(R) 2Watson Files FDA Application for Generic Rozerem(R) 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 2US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 3US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 4US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 5US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 6US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 7US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 8US FDA Approves SEROQUEL XR(R) For Add-On Treatment of Major Depressive Disorder 9Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 2Ambry Genetics and SoftGenetics Form Exclusive Alliance for Extended Bioinformatics Support for Next Generation Sequencing Projects 3Energy saving powder 10692 1Energy saving powder 10692 2Energy saving powder 10692 3Exploration by explosion 3A Studying the inner realm of living cells 10689 1Eisai Donates More Than 80 Murals to Hospitals Around the United States 61147 1Eisai Donates More Than 80 Murals to Hospitals Around the United States 61147 2Eisai Donates More Than 80 Murals to Hospitals Around the United States 61147 3
...ry(1) in the current issue of The Journal of Infec...egalovirus (CMV) said the vaccine under,developmen...ptimal dose and,regimen tested, "holds promise" ba...ponses in a majority of CMV-seronegative subjects,... to prevent infection and disease. The,commentary ...
...c.,(OTC Bulletin Board: ANPG), reported today that...(ESI) announced that the U.S. Environmental,Protec...dditional claims to,its disinfectant/sanitizer, En...gainst the "superbug" MRSA (scientifically known a... VRE (scientifically known as,Vancomycin Resistant...
Other Medicine Technology:Promise of Vical's CMV Vaccine Noted by Independent Experts 2Promise of Vical's CMV Vaccine Noted by Independent Experts 3Promise of Vical's CMV Vaccine Noted by Independent Experts 4Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant 2Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant 3Anpath Group, Inc. Announces Addition of MRSA and VRE Claims for Its EnviroTru(R) Disinfectant 4
(Date:12/5/2009)AVIVA today announced the launch of International Solutions, an innovative new international private medical insurance plan which follows the acclaimed modular design of its UK equivalent. In addition
(Date:12/4/2009)NEW YORK, Dec. 4 Care Investment Trust Inc. (NYSE: CRE ) ("Care" or the "Company") today announced that its Board of Directors has declared a dividend of $0.17 per share of common stock. The div
(Date:12/4/2009)WASHINGTON, Dec. 4 The American Association of Homes and Services for the Aging (AAHSA) applauds the Senate for ensuring that the Community Living and Supportive Services (CLASS) provisions remain i
(Date:12/4/2009)ANAHEIM, Calif., Dec. 4 Pamela Bowen, Chief Information Officer at Crescent Healthcare, was selected as a finalist for the "Chief Innovation Officer" Appy Award for transforming Crescent,s business w
(Date:12/4/2009)STANFORD, Calif. A new study shows that muscle cells grown in the lab can restore an intestine,s ability to squeeze shut properly. The work, performed in dogs and rats, might ultimately help treat pa
Breaking Medicine News(10 mins):Health News:AVIVA's Private Health Insurance Products Solutions Go International 2Health News:Care Investment Trust Inc. Declares Quarterly Dividend of $0.17 Per Share 2Health News:Crescent CIO '09 Dreamforce Conference Speaker and Award Finalist 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 2Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 3Health News:Muscle cell infusion shown to strengthen sphincters in animals in Stanford study 4
...Turner Construction Company, the nation,s largest ...d to construct a $441 million replacement hospital...P) in Plainsboro Township, N.J. , , The scope of... linear accelerators and related ancillary and sup...
...ing with a female mouse can extend the reproductiv...ccording to a study conducted by Ralph Brinster an... Pennsylvania School of Veterinary Medicine. The ...the spermatogonial stem cells likely occurs throug...
.... 22 Nearly 2,500 dentists, dental,hygienists, de...Carolina are,expected to take part in the sixth an... 6, 2009, in what promises to be among the largest...cs and community colleges across the,state to trea...
...ight into a built-in volume-control system, , ...t a natural earplug: Your ears appear to be able t...rotect your hearing, and a new study provides mor...rom dangerous noise, said study author Paul Fuchs,...
...arly free events offered this Saturday, January 24... history-making celebration where yogis, novices, ...ryone in between join together to stretch mind, bo...classes and workshops are free -- or nearly free. ...
...n recent years, genetic studies have uncovered hun... such as cancer or diabetes, raising the prospect ...formation in an individual,s genome. ,But the vari...This disappointment has led geneticist Barak Cohen...
Other Medicine News:Health News:Turner Selected to Construct Replacement Hospital for University Medical Center at Princeton 2Health News:Living with females extends the reproductive life of the male mouse, says Penn veterinary researcher 2Health News:Living with females extends the reproductive life of the male mouse, says Penn veterinary researcher 3Health News:North Carolina Dentists Team Up To Treat Needy Children 2Health News:How the Ear Protects Your Hearing 2Health News:Yoga Day USA Changes Lives and Builds Community 2Health News:Genetic interactions are the key to understanding complex traits 2Health News:Genetic interactions are the key to understanding complex traits 3
Common Duct Exploration Set: With N-Circle® Nitinol Tipless Stone Extractor
MAMMOTOME® HH (Hand Held): 8 Gauge Probe
...wound support. Especially suitable for instances i... is desired and containment of wound transudate is... 910 has been found to be inert, nonantigenic, and...mesh is prepared from a synthetic absorbable copol...
...ing walls of tissue are in direct contact with a s... valleys and ridges means less tissue remodeling t...Forming Plug design fills more of the defect with ... for faster healing and defect containment.,Only ...
Medicine Products: